Celeras Dx’ is a trademark of Cube Dx GmbH. All efforts and products for point of care biomarker testing are bundled under this trademark. Cube Dx was founded in 2015 and is located in St. Valentin (Austria). The company focuses on the development, production and distribution of multiplex tests for in-vitro diagnostics in clinical routine.
Multiplex diagnostics allow for the identification in parallel of a variety of significant parameters (different biomarkers like inflammation markers, kidney markers, infection markers, etc.) in a single test, requiring only a minimal amount of sample material.
Celeras Dx entirely new multiplex technology – the hybcell, world's first cylindrical microarray – delivers speedy and reliableresults with minimal effort. The hyborg – a completely automated device – processes the samples fully independently and without any intervention by the user. The Celeras Dx assay is based on compact profiling and is designed to address especially those complex point of care diagnostic challenges where fast answers are essential.
Celeras Dx' tests have been conceived for the periodic testing of patients during treatment of severe infections in such a manner that the minimum use of samples is involved and a simple and rapid analysis is available. The aim is to deliver a “picture” of the inflammation, organ and coagulation status which is as complete as possible and which quickly indicates any deterioration in the condition of the patient.
(left) Christoph Reschreiter has worked now for fifteen years in the diagnostics industry. Before his entrepreneurial endeavors he worked for the international B&R industry electronics group as the head of international customer projects department. He spent one year in Seoul (Republic of Korea) as an executive manager to set-up the newly founded Korean subsidiary.
(right) Bernhard Ronacher is a molecular biologist, geneticist and biochemist. He had developed the basic idea of the hybcell and founded Cube Dx. During the years 2000 to 2002 he headed the molecular diagnostics laboratory of Lambda GmbH. There he established the DNA array technology. 2001 the first Austrian biochip, ParoCheck, was filed for patent. Bernhard has now worked for almost twenty years in the development of advanced diagnostics solutions.
at DxPx Conference in Duesseldorf, Germany (15th and 16th November, 2022).
at ECCMID in Copenhagen, Denmark (15-18 April, 2023).
Celeras Dx - Part of Cube Dx GmbH | Westbahnstrasse 55 | 4300 St. Valentin (Austria) | email@example.com